ULTIMOVACS ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.93 NOK | -1.42% |
|
-1.84% | -94.36% |
| May. 07 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Ultimovacs ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechCarlos de Sousa (Executives)Good morning, everybody, and thank you for taking ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
7.03
NOK
Average target price
6.5
NOK
Spread / Average Target
-7.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.36% | 22.23M | |
| +18.01% | 47.02B | |
| +48.77% | 41.86B | |
| +0.44% | 41.76B | |
| -4.27% | 28.8B | |
| +11.85% | 26.05B | |
| -22.22% | 19.15B | |
| +4.46% | 12.55B | |
| +29.31% | 12.34B | |
| -3.92% | 11.82B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Transcript : Ultimovacs ASA - Special Call
